A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Phase 2CompletedNCT00482079

Merck Sharp & Dohme LLC743 enrolled

Overview

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

743

Conditions

Diabetes Mellitus, Type II

Interventions

MK0431, sitagliptin phosphate / Duration of Treatment: 21 WeeksDRUG

Comparator: placebo (unspecified) / Duration of Treatment: 21 WeeksDRUG

Eligibility

Sex: ALLMin age: 21 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 21 to 70, You are a man or non-pregnant woman Exclusion Criteria: * Have a history of type I diabetes * You are on a weight loss program with ongoing weight loss or taking weight loss medications * You have a history of minor surgery * You have received investigational drugs within 8 weeks of study start * You have hepatitis B or C

Outcomes

Primary Outcomes

To asses the effectiveness of MK0431 compared to placebo

Time frame: over 12 weeks

Secondary Outcomes

To test the safety and tolerability of MK0431 in patients with type 2 diabetes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.